TG Therapeutics Inc. (TGTX) had a good day on the market for Monday December 09 as shares jumped 30.34% to close at $9.28. About 9.56 million shares traded hands on 45,179 trades for the day, compared with an average daily volume of n/a shares out of a total float of 99.56 million. After opening the trading day at $8.05, shares of TG Therapeutics Inc. stayed within a range of $9.73 to $7.96.
With today’s gains, TG Therapeutics Inc. now has a market cap of $923.93 million. Shares of TG Therapeutics Inc. have been trading within a range of $9.38 and $3.32 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
TG Therapeutics Inc. is based out of New York, NY and has some 120 employees. Its CEO is Michael S. Weiss.
TG Therapeutics Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.